|
|
|
|
|
|
Sponsors and Collaborators: |
Dainippon Sumitomo Pharma Europe LTd. Dainippon Sumitomo Pharma America ICON Clinical Research ClinPhone, Inc. Covance PPD |
Information provided by: | Dainippon Sumitomo Pharma Europe LTd. |
ClinicalTrials.gov Identifier: | NCT00409539 |
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The hypothesis will be tested by measuring the change in mean voids/24 hrs after treatment with SMP-986 compared to placebo, as well comparing the change in: the severity of urgency episodes, mean number of urgency episodes/24 hr, mean number of incontinence episodes/24 hr and the mean void volume/void between SMP-986 and placebo.
Condition | Intervention | Phase |
Overactive Bladder Syndrome (OABS) |
Drug: Placebo Drug: SMP-986 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 10-Week Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20 mg, 40 mg, 80 mg and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome |
Enrollment: | 551 |
Study Start Date: | December 2006 |
Study Completion Date: | July 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Placebo Comparator
Placebo run-in phase. 2 week duration.
|
Drug: Placebo
Placebo, 2 week duration.
|
2: Placebo Comparator
To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
|
Drug: Placebo
Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
|
3: Experimental
20mg dose of SMP-986 to be taken once daily for 8 week duration.
|
Drug: SMP-986
Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
|
4: Experimental
40mg dose of SMP-986 to be taken for 8 week duration.
|
Drug: SMP-986
Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
|
5: Experimental
80mg dose of SMP-986 to be taken for 8 week duration.
|
Drug: SMP-986
Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
|
6: Experimental
120mg dose of SMP-986 to be taken for 8 week duration.
|
Drug: SMP-986
Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
|
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Main Inclusion Criteria:
Exclusion Criteria:
Main Exclusion Criteria:
Patients with the following conditions, or who have undergone the following procedures, will be excluded:
Patients should not have a current or past medical condition contraindicating the use of antimuscarinics and must have discontinued use of the following drugs:
Show 69 Study Locations |
Dainippon Sumitomo Pharma Europe LTd. |
Dainippon Sumitomo Pharma America |
ICON Clinical Research |
ClinPhone, Inc. |
Covance |
PPD |
Principal Investigator: | Prof C Chappel | Royal Hallamshire Hospital |
Responsible Party: | Dainippon Sumitomo Pharma Europe Ltd ( Dainippon Sumitomo Pharma Europe Ltd. ) |
Study ID Numbers: | D3601113 |
First Received: | December 8, 2006 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00409539 |
Health Authority: | United States: Food and Drug Administration; European Union: European Medicines Agency; France: Afssaps - French Health Products Safety Agency; Germany: Federal Institute for Drugs and Medical Devices; Latvia: State Agency of Medicines; Poland: Ministry of Scientific Research and Information Technology; Spain: Comité Ético de Investigación Clínica; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|